Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2007

View Archived Issues

Diabetes snapshots: new data on GLP-1 receptor agonists

Strontium malonate offers better bioavailability than strontium ranelate

Oral fluoroquinolone prodrug safe in monkey studies

Studies reveal properties of potential COPD treatment aclidinium bromide

R-667 alters blood glucose in patients with COPD-emphysema

FDA accepts Nitec's IND for Lodotra

immatics begins phase II study of IMA-901 for renal cell cancer

Alkermes and Indevus state positive results from phase IIa study of ALKS-27 in COPD

Kyorin's novel fluoroquinolone more effective than moxifloxacin in vitro and in vivo

Kyowa Hakko launches Topina in Japan

VaxInnate commences clinical trials with M2e universal influenza vaccine

Santhera to file NDS for SNT-MC17 for Friedreich's ataxia in Canada

Recordati completes double-blind portion of phase III Urief trial for BPH

INCB-9471 safe and well tolerated in clinical studies

Wilex successfully completes WX-671 phase Ib trial in head and neck cancer

Alemtuzumab enters phase III program for MS indication

InterMune's ITMN-191 enters phase Ib trial in chronic HCV patients

Nastech initiates phase II clinical trial for insulin nasal spray

Protherics licenses CoVaccine HT adjuvant to Nobilon

NexMed files NDA for topically applied alprostadil cream

Velcura reports pre-IND meeting with FDA for VEL-0230 for bone disease

Knopp begins phase I trial of small-molecule KNS-760704 for ALS

Update on Pipex's development of oral Coprexa for Wilson's disease

SyntheMed's Repel-CV adhesion barrier recommended approval by FDA panel

Onyvax begins phase IIb trial of cell vaccine Onyvax-P for prostate cancer

FDA issues nonapprovable letter for Novartis' Prexige

MGI Pharma submits NDA to FDA for Aquavan

NeurogesX submits MAA to EMEA for NGX-4010 for peripheral neuropathic pain

Recent patents describe new treatment options for endocrine-related disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...